Skip to main content
. 2020 Aug 15;12(8):2303. doi: 10.3390/cancers12082303

Figure 4.

Figure 4

JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage-mediated ADCP (A–D) Box plot showing ADCP of hMB “Double-Hit” lymphoma cells and J774A.1 macrophages treated with alemtuzumab and (A) erlotinib (EGFR inhibitor), (B) entospletinib (SYK inhibitor, n = 2), (C) ruxolitinib (JAK inhibitor) and (D) tofacitinib (JAK inhibitor). (E) Box plot showing ADCP of JAK2−/− vs empty vector control transduced hMB lymphoma target cells and J774A.1 macrophages treated or not treated with JAK2-inhibitor tofacitinib, ibrutinib and alemtuzumab (n = 2). (F) Kaplan–Meier analysis comparing the survival of wild type (wt) and male JAK2−/− hMB transplanted NSG mice receiving PBS or alemtuzumab. The treatment was given i.p. 10 days after i.v. hMB cell injection. All box plots show the median, the 25th and 75th quartiles, and the minimal and maximal value. Unless otherwise stated experiments were performed of at least three biological replicates. (* p < 0.05, ** p ≤ 0.01 and *** p ≤ 0.001).